Positive AATD Phase 2 Data for Efdoralprin Alfa
Key Questions
What were the key results of the Phase 2 trial for efdoralprin alfa?
Efdoralprin alfa achieved superior functional AAT levels of 24.1 micromolar versus 7.6 for Zemaira, fully maintaining normal levels with q3w dosing. This outperformed the standard therapy in AATD patients.
How does the efdoralprin alfa data de-risk Sanofi's investment?
The positive Phase 2 results support the $2.2B acquisition from Inhibrx and align with new CEO Garijo's R&D priorities. It strengthens rare disease momentum with potential for patient switching.
What advantages does efdoralprin alfa offer over existing AATD treatments?
It sustains normal AAT levels with less frequent dosing than current options like Zemaira. Multiple readouts confirm its actionable superiority in maintaining therapeutic levels.
When might further data on efdoralprin alfa be available?
Additional catalyst events include ATS presentation of the data and potential regulatory or switching updates. These are expected in the coming months as development advances.
What is the broader context for Sanofi's rare disease efforts?
The AATD results complement ongoing pipeline work in rare diseases and immunology. They support Sanofi's strategy under new leadership to prioritize high-potential assets.
Sanofi efdoralprin alfa (ex-Inhibrx) outperforms Zemaira in AATD Ph2 with superior AAT levels (24.1 vs 7.6 micromolar), full normal maintenance, q3w dosing advantage. De-risks $2.2B bet, aligns with new CEO Garijo R&D push and rare-disease momentum; potential multi-week catalyst via ATS data and patient switching. Multiple readouts confirm actionable superiority.